ChemLex
Category: AI in Healthcare
An AI-powered drug discovery and chemical synthesis company with 24/7 autonomous chemistry systems that compress months of synthesis into weeks ChemLex was founded in 2022. The company is led by Sean Lin. Based in Singapore, Singapore. Team size: 10-50. Total funding raised: $71 million. Latest round: Series A+. Key investors include ["Granite Asia","Qiming Venture Partners","LYFE Capital","Sinovation Ventures","MegaRobo"].
- Founded
- 2022
- Headquarters
- Singapore, Singapore
- Team size
- 10-50
- Total funding
- $71 million
Value proposition
To accelerate chemical discovery, reduce time-to-market for new drugs, and provide more cost-efficient and sustainable solutions for chemical synthesis through AI-driven automation
Products and solutions
["AI-driven automated lab for chemical synthesis","Drug discovery services","Drug development services","Self-driving laboratory platforms"]
Unique value
24/7 autonomous 'self-driving' lab for chemical discovery that combines AI with robotics and quantum physics, with dedicated servers ensuring client data is never used for AI training
Target customer
Pharmaceutical and biotechnology companies, research institutions
Industries served
["Pharmaceuticals","Biotechnology","Chemicals","Materials Science"]
Technology advantage
Proprietary AI platform that not only speeds up end-to-end synthesis workflows but also predicts and designs smarter, greener synthesis routes, making processes more cost-effective and sustainable than traditional methods
How they differentiate
ChemLex differentiates through its AI-driven automated lab for chemical synthesis and drug discovery, combining AI, quantum physics, and robotics with emphasis on proprietary AI platform and high-throughput automated systems, while guaranteeing clients that their data is not used for training AI models
Main competitors
["XtalPi","Isomorphic Labs","Recursion Pharmaceuticals","Insilico Medicine","Schrödinger"]
Key partnerships
["Experimental Drug Development Centre (EDDC)","JLABS Asia Pacific (Johnson & Johnson Innovation)"]
Notable customers
["Experimental Drug Development Centre (EDDC)"]
Major milestones
["Founded in 2022","Completed $26 million Series A financing in January 2024","Raised $45 million Series A+ funding led by Granite Asia in December 2025","Established global headquarters and self-driving laboratory in Singapore","Supporting 70+ customers worldwide","Signed MOU with EDDC for drug discovery collaboration"]
Growth metrics
Serving 70+ customers worldwide; recently established Singapore headquarters with plans to hire more hardware/software engineers and chemists
Market positioning
Next-generation AI-for-science company positioned as a leader in autonomous chemical discovery laboratories, focusing on Asia-Pacific with global ambitions
Geographic focus
Founded in China, established global headquarters in Singapore with strong Asia-Pacific focus and global expansion plans
Patents and IP
No publicly available information on patents; company focuses on proprietary AI platform and trade secrets
About Sean Lin
MBA from MIT (2015-2017); Previously affiliated with MIT, Imperial College, and Harvard University's Wyss Institute focusing on chemical synthesis automation and AI
Official website: https://chemlex.com/